Olanzapine — $0 on Listed Strengths

Related medications

Other medications associated with the same conditions in this catalog.

Also listed for Schizophrenia

• Aripiprazole
• Clozapine
• Haloperidol
• Quetiapine
• Risperidone

Other medications in Mental Health

• Paliperidone
• Paroxetine
• Perphenazine
• Phenelzine
• Pimavanserin
• Pimozide
• Prazosin
• Pregabalin

About Olanzapine

Olanzapine is a crucial medication for managing challenging mental health conditions like schizophrenia and bipolar disorder. Understanding your treatment options and costs is vital for consistent care. TheDrugClub is committed to making essential prescriptions, including generic olanzapine, both accessible and affordable, ensuring you can save significantly on your medication expenses every month.

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Olanzapine is approved for (FDA label)

Olanzapine is an atypical antipsychotic indicated: As oral formulation for the: · Treatment of schizophrenia. ( 1.1 ) · Adults: Efficacy was established in three clinical trials in patients with schizophrenia: two 6-week trials and one maintenance trial. ( 14.1 ) · Adolescents (ages 13-17): Efficacy was established in one 6-week trial in patients with schizophrenia ( 14.1 ).

Source: Read the full FDA label on DailyMed. Label effective date: September 8, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Boxed warning for Olanzapine (FDA label)

WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Analyses of seventeen placebo-controlled trials (modal duration of 10 weeks), largely in patients taking atypical antipsychotic drugs, revealed a risk of death in drug-treated patients of between 1.6 to 1.7 times the risk of death in placebo-treated patients. Over the course of a typical 10-week controlled trial, the rate of death in drug-treated patients was about 4.5%, compared to a rate of about 2.6% in the placebo group. Although the causes of death were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature. Observational studies suggest that, similar to atypical antipsychotic drugs, treatment with conventional antipsychotic drugs may increase mortality. The extent to which the findings of increased mortality in observational studies may be attributed to the antipsychotic drug as opposed to some characteristic(s) of the patients is not clear. Olanzapine is not approved for the treatment of patients with dementia-related psychosis [see Warnings and Precautions ( 5.1 ), Use in Specific Populations ( 8.5 ), and Patient Counseling Information ( 17 )] When using olanzapine and fluoxetine in combination, also refer to the Boxed Warning section of the package insert for Symbyax. WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS See full prescribing information for complete boxed warning.

Source: FDA prescribing information (DailyMed). Set ID: 5af81f87-5582-aa23-e063-6294a90a1ee8. SPL document ID: 5af81e66-4aa8-601b-e063-6394a90af5ea. Label effective date: September 8, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Olanzapine (FDA label)

Olanzapine tablets , USP 2.5 mg are white to off white coloured, round shaped, biconvex, film coated tablets debossed 'CL' on one side and '39' on other side, 5 mg, are white to off white coloured, round shaped, biconvex, film coated tablets debossed 'CL 40' on one side and plain on other side, 7.5 mg are white to off white coloured, round shaped, biconvex, film coated tablets debossed 'CL 41' on one side and plain on other side, and 10 mg are white to off white coloured, round shaped, biconvex, film coated tablets debossed 'CL 42' on one side and plain on other side.

Source: FDA prescribing information (DailyMed). Set ID: 5af81f87-5582-aa23-e063-6294a90a1ee8. SPL document ID: 5af81e66-4aa8-601b-e063-6394a90af5ea. Label effective date: September 8, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Olanzapine (FDA label)

When using olanzapine and fluoxetine in combination, also refer to the Adverse Reactions section of the package insert for Symbyax. Most common adverse reactions (≥5% and at least twice that for placebo) associated with: Oral Olanzapine Monotherapy: Schizophrenia (Adults) – postural hypotension, constipation, weight gain, dizziness, personality disorder, akathisia. ( 6.1 ) Schizophrenia (Adolescents) – sedation, weight increased, headache, increased appetite, dizziness, abdominal pain, pain in extremity, fatigue, dry mouth. ( 6.1 ) Manic or Mixed Episodes, Bipolar I Disorder (Adults) – asthenia, dry mouth, constipation, increased appetite, somnolence, dizziness, tremor. ( 6.1 ) Manic or Mixed Episodes, Bipolar I Disorder (Adolescents) – sedation, weight increased, increased appetite, headache, fatigue, dizziness, dry mouth, abdominal pain, pain in extremity. ( 6.1 ) Combination of Olanzapine and Lithium or Valproate: Manic or Mixed Episodes, Bipolar I Disorder (Adults) – dry mouth, weight gain, increased appetite, dizziness, back pain, constipation, speech disorder, increased salivation, amnesia, paresthesia. ( 6.1 ) Olanzapine and Fluoxetine in Combination: Also refer to the Adverse Reactions section of the package insert for Symbyax. ( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Macleods Pharma USA, Inc., at 1-888-943-3210 or 1-855-926-3384 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect or predict the rates observed in practice.

Source: FDA prescribing information (DailyMed). Set ID: 5af81f87-5582-aa23-e063-6294a90a1ee8. SPL document ID: 5af81e66-4aa8-601b-e063-6394a90af5ea. Label effective date: September 8, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Olanzapine (FDA label)

• None with olanzapine tablets monotherapy. • When using olanzapine and fluoxetine in combination, also refer to the Contraindications section of the package insert for Symbyax. • For specific information about the contraindications of lithium or valproate, refer to the Contraindications section of the package inserts for these other products. • None with olanzapine monotherapy. ( 4 ) • When using olanzapine and fluoxetine in combination, also refer to the Contraindications section of the package insert for Symbyax®. ( 4 ) • When using olanzapine in combination with lithium or valproate, refer to the Contraindications section of the package inserts for those products. ( 4 )

Source: FDA prescribing information (DailyMed). Set ID: 5af81f87-5582-aa23-e063-6294a90a1ee8. SPL document ID: 5af81e66-4aa8-601b-e063-6394a90af5ea. Label effective date: September 8, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Olanzapine (FDA label)

The risks of using olanzapine in combination with other drugs have not been extensively evaluated in systematic studies.

Source: FDA prescribing information (DailyMed). Set ID: 5af81f87-5582-aa23-e063-6294a90a1ee8. SPL document ID: 5af81e66-4aa8-601b-e063-6394a90af5ea. Label effective date: September 8, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.